P1.01-057 Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
نویسندگان
چکیده
منابع مشابه
phase ii study of gemcitabine and cisplatin regimen in advanced non-small cell lung cancer (nsclc).
background: cisplatin-based chemotherapy is the standard treatment for advanced non-small cell lung cancer (nsclc). many novel drugs, including gemcitabine, vinorelbine, paclitaxel and docetaxel have been used in combination with cisplatin in this setting. of these drugs, gemcitabine is reported to have a high response rate and acceptable toxicity. the aim of this study was to evaluate the effi...
متن کاملErlotinib in previously treated non-small-cell lung cancer.
BACKGROUND We conducted a randomized, placebo-controlled, double-blind trial to determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lung cancer after the failure of first-line or second-line chemotherapy. METHODS Patients with stage IIIB or IV non-small-cell lung cancer, with performance status from 0 to 3, were eligible if they had r...
متن کاملComparative Efficacy Of Treatments For Previously Treated Advanced Or Metastatic Non-Small Cell Lung Cancer (Nsclc): A Network Meta-Analysis.
s excluded (Level I) -Duplicates (N=3) -Ineligible study population (N=369) -Ineligible intervention (N=1592) -Ineligible study design or publication type (N=1849) -Ineligible outcomes (N=202) -Abstract not in English (N=3) Abstracts excluded (Level II) -Duplicates (N=12) -Ineligible study population (N=11) -Ineligible intervention (N=88) -Ineligible study design or publication type (N=28) -Ine...
متن کاملEfficacy and Safety of Erlotinib in Previously Treated Advanced Non-Small Cell Lung Cancer
Erlotinib is a potent inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, with single-agent antitumor activity which improves symptom control and quality of life compared with placebo in non-small-cell-lung cancer (NSCLC) patients. We aimed to determine the efficacy and safety of the second, third or fourth–line erlotinib in advanced NSCLC patients in Turkish population. E...
متن کاملGefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy
The activation of lymphocytes by gefitinib treatment has been described. In this phase II pilot trial, we explored the possible synergism between IL-2 and gefitinib for non-small cell lung cancer (NSCLC) treatment. From September, 2003, to November, 2006, 70 consecutive patients with advanced, progressive NSCLC, previously treated with chemotherapy, received oral gefitinib 250 mg daily. The fir...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2017
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2017.09.711